Patents Assigned to Athersys, Inc.
  • Patent number: 9962407
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: May 8, 2018
    Assignees: Athersys, Inc., Oregon Health and Science University
    Inventors: Robert Deans, Wouter Van't Hof, Richard Maziarz, Magdalena Kovacsovics, Philip Streeter
  • Patent number: 9808485
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: November 7, 2017
    Assignees: Athersys, Inc., Oregon Health And Science University
    Inventors: Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
  • Patent number: 8716324
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: May 6, 2014
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
  • Patent number: 8716276
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds. These compounds are serotonin receptor (5-HT2c) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT2c) is desired (e.g. addiction, anxiety, depression, obesity, and others).
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: May 6, 2014
    Assignee: Athersys, Inc.
    Inventors: L. Nathan Tumey, David C. Bom, Youssef L. Bennani, Michael J. Robarge
  • Patent number: 8232311
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: July 31, 2012
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
  • Patent number: 8147824
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Grant
    Filed: November 9, 2005
    Date of Patent: April 3, 2012
    Assignees: Athersys, Inc., Oregon Health and Science University
    Inventors: Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
  • Patent number: 8129424
    Abstract: This invention relates to compounds having pharmacological activity, to compositions containing these compounds, and to a method of treatment employing the compounds and compositions. More particularly, this invention concerns certain indole derivatives and their salts and solvates. These compounds have H3 histamine receptor antagonist activity. This invention also relates to pharmaceutical compositions containing these compounds and to a method of treating disorders in which histamine H3 receptor blockade is beneficial.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: March 6, 2012
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, Michael G. Campbell, David Dastrup, Emilie Porter Huck
  • Patent number: 7981896
    Abstract: This invention relates to compounds of the formula: to compositions containing these compounds, and to methods of treatment employing the compounds and compositions.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: July 19, 2011
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, Michael G. Campbell, David Dastrup, Emilie Porter Huck
  • Patent number: 7981919
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Grant
    Filed: August 5, 2008
    Date of Patent: July 19, 2011
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, David C. Bom, Michael J. Robarge
  • Patent number: 7947691
    Abstract: Acrylic n-hydroxy imides and their use in pharmaceutical compositions and in the inhibition of flap endonuclease are disclosed.
    Type: Grant
    Filed: July 20, 2005
    Date of Patent: May 24, 2011
    Assignee: Athersys, Inc.
    Inventors: Lawrence N. Tumey, Youssef Bennani, Bayard Huck, David C. Bom
  • Patent number: 7935830
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: May 3, 2011
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
  • Patent number: 7897634
    Abstract: This invention relates to compounds of the formulas (1), (2) and (3) having pharmacological activity, to compositions containing these compounds, and to methods of treatment employing the compounds and compositions.
    Type: Grant
    Filed: January 30, 2007
    Date of Patent: March 1, 2011
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, Michael G. Campbell, David Dastrup, Emile Porter Huck
  • Patent number: 7893051
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds. These compounds are serotonin receptor (5-HT2c) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT2c) is desired (e.g. addiction, anxiety, depression, obesity, and others).
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: February 22, 2011
    Assignee: Athersys, Inc.
    Inventors: L. Nathan Tumey, David C. Bom, Youssef L. Bennani, Michael J. Robarge
  • Patent number: 7855224
    Abstract: This invention relates to compounds having pharmacological activity, to compositions containing these compounds, and to a method of treatment employing the compounds and compositions. More particularly, this invention concerns certain indole derivatives and their salts and solvates. These compounds have H3 histamine receptor antagonist activity. This invention also relates to pharmaceutical compositions containing these compounds and to a method of treating disorders in which histamine H3 receptor blockade is beneficial.
    Type: Grant
    Filed: September 23, 2008
    Date of Patent: December 21, 2010
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, Michael G. Campbell, David Dastrup, Emilie Porter Huck
  • Patent number: 7718647
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: May 18, 2010
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, Michael J. Robarge, David C. Bom, Norbert Varga, Lawrence N. Tumey
  • Patent number: 7528262
    Abstract: This invention relates to compounds having pharmacological activity, to compositions containing these compounds, and to a method of treatment employing the compounds and compositions. More particularly, this invention concerns certain indole derivatives and their salts and solvates. These compounds have H3 histamine receptor antagonist activity. This invention also relates to pharmaceutical compositions containing these compounds and to a method of treating disorders in which histamine H3 receptor blockade is beneficial.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: May 5, 2009
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, Michael G. Campbell, David Dastrup, Emilie Porter Huck
  • Patent number: 7423056
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Grant
    Filed: September 1, 2005
    Date of Patent: September 9, 2008
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, David C. Bom, Michael J. Robarge
  • Patent number: 7319103
    Abstract: This invention relates to compounds having pharmacological activity, to compositions containing these compounds, and to a method of treatment employing the compounds and compositions. More particularly, this invention concerns certain non-imidazole tertiary amine derivatives and their salts and solvates. These compounds have H3 histamine receptor antagonist activity. This invention also relates to pharmaceutical compositions containing these compounds and to a method of treating disorders in which histamine H3 receptor blockade is beneficial.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: January 15, 2008
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, James T. Anderson, Jianmin Wang, Michael G. Campbell
  • Patent number: 7316923
    Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more amplifiable markers located on the integrated vector. In another embodiment, the invention is directed to activation of endogenous genes by non-targeted integration of specialized activation vectors, which are provided by the invention, into the genome of a host cell.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: January 8, 2008
    Assignee: Athersys, Inc.
    Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
  • Patent number: 7033782
    Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. Thus, by the present invention, endogenous genes, including those associated with human disease and development, may be activated and isolated without prior knowledge of the sequence, structure, function, or expression profile of the genes.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: April 25, 2006
    Assignee: Athersys, Inc.
    Inventor: John J. Harrington